Officer Ho Files To Sell 1,882 Of Denali Therapeutics Inc [DNLI]

Officer Carole Ho of Denali Therapeutics Inc filed a Form 144 with the SEC to sell 1,882 restricted shares on December 4, 2025, through Morgan Stanley Smith Barney LLC, under a prearranged trading plan (10b5-1).

Denali Therapeutics shares are trading higher after the company and Royalty Pharma announced a $275 million synthetic royalty funding agreement.

Denali Therapeutics Hosts Investor Day, Updates Pipeline

Denali Therapeutics held its Investor Day on December 4, 2025, updating stakeholders on its development programs. Highlights include the FDA review of tividenofusp alfa for Hunter Syndrome, progress on DNL126 for Sanfilippo Syndrome, and TAK-594 for Frontotemporal Dementia. Minimal delays are expected in the Pompe Disease program. The company is preparing for potential commercial launches in 2026 and 2027. Analysts rate DNLI stock as a Buy with a $32.00 price target, despite financial challenges and a bearish technical outlook.

Denali Therapeutics Secures $275 Million Royalty Deal With Royalty Pharma

Denali Therapeutics Inc. has partnered with Royalty Pharma plc in a $275 million synthetic royalty funding agreement for tividenofusp alfa, an investigational therapy for Hunter syndrome. Royalty Pharma will pay $200 million upon FDA approval and $75 million upon European approval by 2029. In return, they will receive a 9.25% royalty on worldwide net sales until a specified return multiple is reached.

H.C. Wainwright Keeps Their Buy Rating on Denali Therapeutics (DNLI)

H.C. Wainwright analyst Andrew Fein maintains a Buy rating on Denali Therapeutics, setting a price target of $32.00. Shares closed at $19.00, with a consensus price target of $31.00, indicating a 63.16% upside. B. Riley Securities also maintains a Buy rating with a $30.00 target. Fein has a 26.5% average return and a 54.36% success rate on stocks.